Dr. Yu on the Utility of Enfortumab Vedotin in Metastatic Urothelial Cancer

Video

In Partnership With:

Evan Y. Yu, MD, discusses the utility of enfortumab vedotin-ejfv in patients with locally advanced or metastatic urothelial cancer. 

Evan Y. Yu, MD, clinical research director, Genitourinary Medical Oncology, Seattle Cancer Care Alliance, professor of medical oncology, University of Washington School of Medicine, professor in the clinical research, Fred Hutchinson Cancer Research Center, medical director, clinical research support, Fred Hutchinson Cancer Research Consortium, discusses the utility of enfortumab vedotin-ejfv (Padcev) in patients with locally advanced or metastatic urothelial cancer. 

Enfortumab vedotin has elicited a significant overall survival (OS) benefit when administered in the third-line setting for this patient population, according to recent data published in the New England Journal of Medicine. Therefore, following avelumab (Bavencio) maintenance therapy, enfortumab vedotin can be used as a default agent in this setting, according to Yu. 

Additionally, erdafitinib (Balversa) can be utilized in patients who have an FGFR alteration, although it is easy to gravitate toward enfortumab vedotin due to the level 1 evidence and OS benefit that has been demonstrated with agent, Yu concludes. 

Related Videos
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD